Real-world treatment persistence among advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or adalimumab

This study compared persistence among ADT-experienced patients with UC initiated on ustekinumab (anti-interleukin 12/23 antibody), or adalimumab (anti-tumor necrosis factor biologic).

Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, Sabree Burbage, Aditi Shah, Jill Korsiak, Patrick Lefebvre, Caroline Kerner, Dominic Pilon Source Type: research